Recommendation: Buy
| Entry Date | Symbol | Recommendation | Entry Price (USD) | Target 1 (USD) | Target 2 (USD) | Holding Duration | Position Status | Return(%)* |
|---|---|---|---|---|---|---|---|---|
| 27 Feb, 26 | ETON | Buy | USD 17.25 | USD 18.2 | USD 19.2 | 13 days | Closed |
11.48%
|
*Return(%) represent the percentage change between the entry price and exit price of the recommendation.
Data Powered by EOD Historical Data (“EODHD”).
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Strong Acceleration in Product Sales and Royalties: Product sales and royalties increased to USD 22.46 million in Q3 FY25 from USD 9.82 million in Q3 FY24
Revenue More Than Doubled Year-over-Year: In Q3 FY25, Eton Pharmaceuticals reported total net revenues of USD 22.46 million, compared to USD 10.32 million in Q3 FY24, representing an increase of approximately 118% year-over-year
Rising Operating Expenses: Total operating expenses rose to USD 9.22 million in Q3 FY25 compared to USD 5.79 million in Q3 FY24
Sharp Increase in Cost of Sales: Cost of sales increased significantly to USD 14.60 million in Q3 FY25 from USD 4.02 million in Q3 FY24
Eton Pharmaceuticals faces material investment risk arising from margin compression due to rising cost of sales and operating expenses, customer concentration in specialty pharmacies, reliance on product acquisitions, and the need to sustain revenue growth to offset increasing debt and interest obligations
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 17.25 | 15.5 | 18.2 | 19.2 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Strong Revenue Expansion Driven by Product Portfolio Growth: During Q3 FY25, Eton reported total net revenues of USD 22.46 million, compared to USD 10.32 million in Q3 FY24, reflecting robust year-over-year growth primarily driven by product sales and royalties. Product sales and royalties increased to USD 22.46 million from USD 9.82 million, more than doubling year-over-year. For the nine months ended September 30, 2025, total net revenues rose to USD 58.67 million, compared to USD 27.36 million in the prior-year period, highlighting sustained commercial traction across its rare disease portfolio.
Margin Compression Amid Higher Cost of Sales: Despite significant revenue growth, cost of sales increased materially. In Q3 FY25, total cost of sales rose to USD 14.60 million from USD 4.02 million in Q3 FY24. Consequently, gross profit improved to USD 7.86 million versus USD 6.30 million in Q3 FY24, but gross margin declined due to higher product-related costs and inventory step-ups.
Elevated Operating Expenses Reflecting Commercial Scale-Up: Operating expenses expanded meaningfully during the quarter. Research and development expenses increased to USD 1.11 million from USD 0.51 million, while general and administrative expenses rose to USD 8.11 million from USD 5.29 million in Q3 FY24. As a result, total operating expenses increased to USD 9.22 million compared to USD 5.79 million in the prior-year quarter, reflecting investments in commercialization, infrastructure, and pipeline advancement.
Shift from Profit to Quarterly Loss: The company recorded an operating loss of USD 1.36 million in Q3 FY25 compared to operating income of USD 0.51 million in Q3 FY24. Net loss for the quarter stood at USD 1.93 million, versus net income of USD 0.63 million in Q3 FY24, primarily due to higher operating costs and increased interest expense.
Strengthened Cash Position and Asset Base: Cash and cash equivalents increased significantly to USD 37.12 million as of September 30, 2025, compared to USD 14.94 million at December 31, 2024. Total assets rose to USD 104.51 million from USD 76.12 million, reflecting growth in receivables, inventory, and intangible assets associated with product acquisitions.
Increased Liabilities and Accumulated Deficit: Total liabilities increased to USD 81.38 million from USD 51.70 million, driven by higher accounts payable and accrued Medicaid rebates. Accumulated deficit widened to USD 113.98 million compared to USD 107.89 million at year-end 2024, reflecting continued net losses on a year-to-date basis.
Considering recent key business, financial updates, current trading levels, and key business risks, a ‘Buy’ recommendation has been given to Eton Pharmaceuticals, Inc (NASDAQ: ETON) at the closing market price of USD 17.25, as on Feb 26, 2026
Data Powered by EOD Historical Data (“EODHD”).
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ETON Eton Pharmaceuticals Inc |
-0.29 0.89% | 32.47 | 120.00 | 64.94 | 2.78 | 5.71 | 2.29 | -248.7317 |
| ZTS Zoetis Inc |
1.45 1.88% | 78.71 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
- -% | 30.75 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 157.12 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| GALDY GALDERMA GROUP AG |
-0.33 0.76% | 42.94 | 74.21 | 41.67 | 8.64 | 5.55 | 9.15 | 42.22 |
Data Powered by EOD Historical Data (“EODHD”).
Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels as on February 27, 2026. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned has been achieved and is subject to the factors discussed above.
Note 4: StockNextt reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.
Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report has been issued by StockNextt which has an Ontario Business Identification Number 1000958347 and British Columbia registration Number FM1051529 is a trade name under Kalkine Canada Advisory Services Inc. having Business Number 761925130BC0001. Kalkine Canada Advisory Services Inc. and StockNextt are collectively referred to as “StockNextt”, “we”, “us”, and “our”. The website https://stocknextt.com and associated pages are published by StockNextt. The information in this report and on the StockNextt website has been prepared from a wide variety of sources, which StockNextt, to the best of its knowledge and belief, considers accurate. StcokNextt has made every effort to ensure the reliability of information contained in its reports, newsletters, and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations for investing in securities and other financial products. StockNextt does not offer financial advice based upon your personal financial situation or goals, and we shall not be held liable for any investment or trading losses you may incur by using the opinions expressed in our reports, publications, market updates, news alerts and corporate profiles. StockNextt does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. StockNextt’s general advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested. Please also read our Terms and conditions for further information. Employees and/or associates of StockNextt and its related entities may hold an interest in the securities or other financial products covered in this report or on the StockNextt website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Copyright © 2026 Krish Capital Pty Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.
Australia